- Type / Class
- Equity / Common Stock
- Shares outstanding
- 61,152,075
- Total 13F shares
- 20,898,775
- Share change
- +248,180
- Total reported value
- $585,169,000
- Price per share
- $28.00
- Number of holders
- 34
- Value change
- +$9,050,400
- Number of buys
- 16
- Number of sells
- 15
Quarterly Holders Quick Answers
What is CUSIP 04351P101?
CUSIP 04351P101 identifies ASND - Ascendis Pharma A/S - Common Stock in SEC institutional holdings data.
Need full ownership history?
Open the full security ownership history page.
Next holder-history checks
These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.
- Back to full security ownership history for the broader multi-quarter picture.
- Latest 13F filings for newly reported positions across managers.
- Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
- SEC investors directory for manager drilldown.
Explore More Reporting Periods
Jump to adjacent filing periods for faster comparison and easier crawl discovery.
Recent filing periods for CUSIP 04351P101:
Top shareholders of ASND - Ascendis Pharma A/S - Common Stock (13F + 13D/G + 3/4/5)
Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.
Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.
| Holder | Source | Role / Reporting | Ownership % | Shares | Holdings Value | 12M Net Δ | As of | Details |
|---|---|---|---|---|---|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. |
13F
|
Company |
8.8%
|
5,409,990
|
$109,498,000 | — | 31 Dec 2016 | |
| FMR LLC |
13F
|
Company |
5.2%
|
3,152,532
|
$63,807,000 | — | 31 Dec 2016 | |
| ORBIMED ADVISORS LLC |
13F
|
Company |
4.4%
|
2,717,315
|
$54,998,000 | — | 31 Dec 2016 | |
| Vivo Capital, LLC |
13F
|
Company |
2.9%
|
1,766,832
|
$35,761,000 | — | 31 Dec 2016 | |
| DEERFIELD MANAGEMENT COMPANY, L.P. |
13F
|
Company |
1.7%
|
1,050,000
|
$21,252,000 | — | 31 Dec 2016 | |
| BAKER BROS. ADVISORS LP |
13F
|
Company |
1.7%
|
1,023,266
|
$20,711,000 | — | 31 Dec 2016 | |
| EcoR1 Capital, LLC |
13F
|
Company |
1.6%
|
975,700
|
$19,748,000 | — | 31 Dec 2016 | |
| VHCP Management II, LLC |
13F
|
Company |
1.2%
|
721,152
|
$14,596,000 | — | 31 Dec 2016 | |
| JANUS HENDERSON INVESTORS US LLC |
13F
|
Company |
0.97%
|
594,295
|
$12,029,000 | — | 31 Dec 2016 | |
| ACUTA CAPITAL PARTNERS, LLC |
13F
|
Company |
0.94%
|
575,309
|
$11,644,000 | — | 31 Dec 2016 | |
| Avoro Capital Advisors LLC |
13F
|
Company |
0.89%
|
545,203
|
$11,035,000 | — | 31 Dec 2016 | |
| SPHERA FUNDS MANAGEMENT LTD. |
13F
|
Company |
0.53%
|
326,622
|
$6,611,000 | — | 31 Dec 2016 | |
| Rock Springs Capital Management LP |
13F
|
Company |
0.53%
|
325,000
|
$6,578,000 | — | 31 Dec 2016 | |
| EVENTIDE ASSET MANAGEMENT, LLC |
13F
|
Company |
0.37%
|
229,000
|
$4,635,000 | — | 31 Dec 2016 | |
| MILLENNIUM MANAGEMENT LLC |
13F
|
Company |
0.37%
|
226,804
|
$4,591,000 | — | 31 Dec 2016 | |
| Foresite Capital Management III, LLC |
13F
|
Company |
0.29%
|
180,000
|
$3,643,000 | — | 31 Dec 2016 | |
| Cormorant Asset Management, LP |
13F
|
Company |
0.27%
|
162,254
|
$3,284,000 | — | 31 Dec 2016 | |
| EMORY UNIVERSITY |
13F
|
Company |
0.17%
|
104,793
|
$2,121,000 | — | 31 Dec 2016 | |
| NEXTHERA CAPITAL LP |
13F
|
Company |
0.16%
|
100,000
|
$2,024,000 | — | 31 Dec 2016 | |
| VHCP Management, LLC |
13F
|
Company |
0.15%
|
90,000
|
$1,822,000 | — | 31 Dec 2016 | |
| MARSHALL WACE, LLP |
13F
|
Company |
0.14%
|
87,558
|
$1,772,000 | — | 31 Dec 2016 | |
| Laurion Capital Management LP |
13F
|
Company |
0.14%
|
83,200
|
$1,684,000 | — | 31 Dec 2016 | |
| DAFNA Capital Management LLC |
13F
|
Company |
0.09%
|
53,000
|
$1,073,000 | — | 31 Dec 2016 | |
| ALPS ADVISORS INC |
13F
|
Company |
0.05%
|
30,296
|
$613,000 | — | 31 Dec 2016 | |
| HIGHBRIDGE CAPITAL MANAGEMENT LLC |
13F
|
Company |
0.03%
|
20,000
|
$405,000 | — | 31 Dec 2016 | |
| WELLS FARGO & COMPANY/MN |
13F
|
Company |
0.01%
|
5,247
|
$106,000 | — | 31 Dec 2016 | |
| BANK OF AMERICA CORP /DE/ |
13F
|
Company |
0.01%
|
4,325
|
$88,000 | — | 31 Dec 2016 | |
| MORGAN STANLEY |
13F
|
Company |
0%
|
662
|
$13,000 | — | 31 Dec 2016 | |
| Tower Research Capital LLC (TRC) |
13F
|
Company |
0%
|
609
|
$12,000 | — | 31 Dec 2016 | |
| UBS Group AG |
13F
|
Company |
0%
|
200
|
$4,000 | — | 31 Dec 2016 | |
| US BANCORP \DE\ |
13F
|
Company |
0%
|
76
|
$2,000 | — | 31 Dec 2016 |
Institutional Holders of Ascendis Pharma A/S - Common Stock (ASND) as of Q1 2017
As of 31 Mar 2017,
Ascendis Pharma A/S - Common Stock (ASND) was held by
34 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
20,898,775 shares.
The largest 10 holders included
RA CAPITAL MANAGEMENT, LLC, FMR LLC, ORBIMED ADVISORS LLC, Vivo Capital, LLC, BAKER BROS. ADVISORS LP, EcoR1 Capital, LLC, DEERFIELD MANAGEMENT CO, VHCP Management II, LLC, venBio Select Advisor LLC, and JANUS CAPITAL MANAGEMENT LLC.
This page lists
34
institutional shareholders reporting positions in this security
for the Q1 2017 filing period.
| Investor | Option | Weight % | Change % | Value $ | * Price | Shares | Share Change | Activity | Report Period |
|---|
Compare Q1 2017 vs Q4 2016 Across Filers
Q4 2016 holders
31
Q1 2017 holders
34
Holder diff
3
| Investor | Q4 2016 Shares | Q1 2017 Shares | Share Diff | Share Chg % | Q4 2016 Value $ | Q1 2017 Value $ | Value Diff $ | Value Chg % |
|---|
Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).
Quarterly Holders Trend
Quarterly Value Trend
Quarterly Shares Trend
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.
An asterisk sign (*) next to the price indicates that the price is likely invalid.